Biogen TYSABRI revenue
TYSABRI revenue at Biogen came to $437.1M for the quarter to 30 Sep 2026, up 1.2% from a year earlier.
As Biogen reported it in its earnings release and quarterly or annual report, compiled and checked by AapWire. Latest figure filed 28 Oct 2026.
By quarter
| Period ending | TYSABRI revenue | Change on a year | Filed |
|---|---|---|---|
| 30 Sep 2026 | $437.1M | up 1.2% | 28 Oct 2026 |
| 30 Jun 2026 | $450.8M | down 0.8% | 29 Jul 2026 |
| 31 Mar 2026 | $441.5M | up 15.7% | 29 Apr 2026 |
| 31 Dec 2025 | $397.5M | down 4.3% | 6 Feb 2026 |
| 30 Sep 2025 | $431.8M | up 6.3% | 30 Oct 2025 |
| 30 Jun 2025 | $454.6M | down 1.6% | 31 Jul 2025 |
| 31 Mar 2025 | $381.5M | down 11.5% | 1 May 2025 |
| 31 Dec 2024 | $415.4M | down 10.6% | 12 Feb 2025 |
| 30 Sep 2024 | $406.1M | down 11.0% | 30 Oct 2024 |
| 30 Jun 2024 | $462.2M | down 4.3% | 1 Aug 2024 |
| 31 Mar 2024 | $431.3M | down 8.8% | 24 Apr 2024 |
| 31 Dec 2023 | $464.7M | down 4.9% | 14 Feb 2024 |
| 30 Sep 2023 | $456.3M | down 9.7% | 8 Nov 2023 |
| 30 Jun 2023 | $483.1M | down 6.4% | 25 Jul 2023 |
| 31 Mar 2023 | $472.8M | down 9.2% | 25 Apr 2023 |
| 31 Dec 2022 | $488.4M | down 4.7% | 15 Feb 2023 |
| 30 Sep 2022 | $505.5M | down 3.3% | 25 Oct 2022 |
| 30 Jun 2022 | $516.2M | down 1.5% | 20 Jul 2022 |
| 31 Mar 2022 | $520.8M | up 3.5% | 3 May 2022 |
| 31 Dec 2021 | $512.7M | up 7.9% | 3 Feb 2022 |
| 30 Sep 2021 | $522.8M | up 1.2% | 20 Oct 2021 |
| 30 Jun 2021 | $524.2M | up 21.3% | 22 Jul 2021 |
| 31 Mar 2021 | $503.3M | down 3.7% | 22 Apr 2021 |
| 31 Dec 2020 | $475.2M | up 0.5% | 3 Feb 2021 |
| 30 Sep 2020 | $516.5M | up 6.8% | 21 Oct 2020 |
| 30 Jun 2020 | $432.0M | down 9.1% | 22 Jul 2020 |
| 31 Mar 2020 | $522.4M | up 13.5% | 23 Apr 2020 |
| 31 Dec 2019 | $472.9M | up 1.8% | 6 Feb 2020 |
| 30 Sep 2019 | $483.6M | up 2.8% | 22 Oct 2019 |
| 30 Jun 2019 | $475.3M | up 1.7% | 24 Jul 2019 |
| 31 Mar 2019 | $460.4M | down 0.4% | 24 Apr 2019 |
| 31 Dec 2018 | $464.5M | — | 6 Feb 2019 |
| 30 Sep 2018 | $470.2M | up 0.2% | 23 Oct 2018 |
| 30 Jun 2018 | $467.2M | down 5.8% | 24 Jul 2018 |
| 31 Mar 2018 | $462.1M | — | 24 Apr 2018 |
| 30 Sep 2017 | $469.4M | — | 24 Oct 2017 |
| 30 Jun 2017 | $496.0M | — | 25 Jul 2017 |
Definition
Revenue from this part of the business, as the company names and reports it in its results. Each figure is read from the table or sentence the company printed and kept with its scale and decimals; see data and methodology.
Other operating KPIs of Biogen: Product revenue, net revenue · MS Product Revenues · Rare Disease Product Revenue · Revenue from anti-CD20 therapeutic programs revenue · SPINRAZA revenue · Royalty Attributed To OCREVUS revenue · Fumarate revenue · Specialized Immunology revenue · Interferon revenue · VUMERITY revenue · SYFOVRE revenue · SKYCLARYS revenue · Biosimilars revenue · AVONEX revenue · Contract manufacturing, royalty and other revenue · Contract manufacturing revenue · BENEPALI revenue · ZURZUVAE revenue · TECFIDERA revenue · Alzheimer's Collaboration revenue · PLEGRIDY revenue · EMPAVELI revenue · IMRALDI revenue · QALSODY revenue · financial statements
Every KPI and segment of BIIB, in the terminal.
Ten years of operating figures, segments, guidance against results, charts and alerts on each new release.
